5 benign urology headlines you missed in Q2 2026

The second quarter of 2026 saw continued momentum across benign urology, with important regulatory developments, emerging clinical evidence, and advances in medical technology shaping the field. From proposed updates to testosterone replacement therapy labeling to the approval of the first oral carbapenem for complicated urinary tract infections, these headlines have the potential to influence clinical practice and future research.